PTC Therapeutics appoints Jessica Chutter, former Morgan Stanley biotech banker, to board
PTC Therapeutics appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director. Ms. Chutter retired from Morgan Stanley in February 2026 after more than 40 years in healthcare investment banking, and she received standard outside director pay and equity grants.
Key points
- Appointed March 24, 2026, as a Class I director with a term expiring at the 2026 annual meeting
- Receives a $50,000 base annual retainer under the outside director compensation policy
- Initial grant of 3,475 stock options and 4,000 restricted stock units, plus a pro-rated 2026 annual grant of 2,896 options and 3,333 RSUs
- Previously Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley; company says she was involved in about $80 billion of capital raising and $85 billion of strategic transactions
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 25, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.